FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer

BACKGROUND: In patients with colorectal liver metastases (CLM) R0 resection significantly improves overall survival (OS). METHODS: In this report, we present the results of a phase II trial of FOLFOX6+bevacizumab in patients with non-optimally resectable CLM. Patients received six cycles of FOLFOX6+...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Bertolini, F, Malavasi, N, Scarabelli, L, Fiocchi, F, Bagni, B, Giovane, C Del, Colucci, G, Gerunda, G E, Depenni, R, Zironi, S, Fontana, A, Pettorelli, E, Luppi, G, Conte, P F
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2011
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3068493/
https://ncbi.nlm.nih.gov/pubmed/21386839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.43
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky